TherapeuticsMD, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $1.3M | $70.0M | $2.6M |
| Gross profit | — | — | $1.3M | $68.6M | $1.2M |
| Operating income | -$4.4M | -$6.1M | -$8.5M | $1.2M | -$79.6M |
| Operating expenses | $7.4M | $7.9M | $9.8M | $67.4M | $80.7M |
| Cost of revenue | — | — | — | $1.4M | $1.4M |
| Cash from operations | $2.5M | $1.2M | -$23.1M | $9.4M | -$142.7M |
| Capital expenditure | — | — | — | — | $34,000 |
| Free cash flow | — | — | — | — | -$142.7M |
| Impairments | — | $1.3M | — | — | — |
| Total assets | $37.7M | $38.8M | $43.3M | $90.5M | $169.5M |
| Total liabilities | $10.8M | $11.5M | $14.0M | $55.3M | $263.1M |
Shares outstanding 11.6M · Free float 98.3%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.